Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
Active, not recruiting · NCT03795207 · Registry updated 2026-03-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) | Bone Metastases; Node; Prostate; Prostate Cancer Patients | Active, not recruiting | Phase 2 | 2026-03-31 | NCT03795207 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Institut Cancerologie de l'Ouest | 27 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Georges François Leclerc | Dijon | France | 42 |
| Centre Léon Bérard | Lyon | France | 77 |
| Centre Oscar Lambret | Lille | France | 73 |
| CHBS Lorient | Lorient | France | 2 |
| CHRU de Brest | Brest | France | 7 |
| Hospices Civils de Lyon | Pierre-Bénite | France | 5 |
| ICO | Saint-Herblain | France | 2 |
| Institut Bergonie | Bordeaux | France | 53 |
| Institut de Cancérologie de Montpellier | Montpellier | France | 4 |